Stockscreener 앱 받기
32.33
11.71%
3.39
시간 외 거래:
32.04
-0.29
-0.90%
전일 마감가:
$28.94
열려 있는:
$29.28
하루 거래량:
340.85K
Relative Volume:
1.99
시가총액:
$504.86M
수익:
$925.00K
순이익/손실:
$-90.35M
주가수익비율:
-6.8628
EPS:
-4.7109
순현금흐름:
$-78.52M
1주 성능:
+22.09%
1개월 성능:
+57.94%
6개월 성능:
+21.27%
1년 성능:
+147.74%
1일 변동 폭
$29.28
$33.18
1주일 범위
$24.88
$33.18
52주 변동 폭
$12.97
$37.27
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
32.33 | 451.92M | 925.00K | -90.35M | -78.52M | -4.7109 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Craig Hallum | Buy |
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Cvijic to Sell 14,400 Neurogene Shares (NGNE) via J.P. Morgan - Stock Titan
New Neurogene commercial chief gets 120,000-share hiring grant - Stock Titan
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth - Yahoo Finance
Jennison Associates LLC Increases Holdings in Neurogene Inc. $NGNE - MarketBeat
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc. - Traders Union
Guggenheim reiterates Neurogene stock rating with $69 target By Investing.com - Investing.com Australia
Guggenheim Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $69 - Moomoo
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy - ChartMill
Guggenheim reiterates Neurogene stock rating with $69 target - Investing.com
NGNE Neurogene posts narrower Q4 2025 loss than consensus estimates, edges down modestly in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai
Neurogene (NGNE) Chief Commercial Officer listed in new Form 3 - Stock Titan
Neurogene names commercial chief, adds board member By Investing.com - Investing.com Australia
Neurogene (NGNE) Stock: Is It Showing Downtrend Signals (Bullish Sentiment) 2026-04-20Top Breakouts - Xã Thanh Hà
Neurogene appoints Christy Shafer as CCO - The Pharma Letter
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail to Board of Directors; Advances NGN-401 Gene Therapy for Rett Syndrome - Minichart
Neurogene names commercial chief, adds board member - Investing.com
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization - TipRanks
Neurogene appoints Christy Shafer as chief commercial officer and Christine Mikail, J.D., to board of directors - marketscreener.com
Neurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine Mikail to board - Traders Union
New CCO and board role strengthen Neurogene (NASDAQ: NGNE) leadership - Stock Titan
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors - marketscreener.com
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth - simplywall.st
[ARS] Neurogene Inc. SEC Filing - Stock Titan
Neurogene (NASDAQ: NGNE) 2026 proxy sets director, pay and auditor votes - Stock Titan
Neurogene Inc. (NGNE) Stock Analysis: Exploring a 223% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Neurogene downgraded to Neutral at Baird on regulatory uncertainty - MSN
Risk Check: Will Neurogene Inc outperform the market in YEAR2026 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Published on: 2026-04-11 06:56:54 - baoquankhu1.vn
Neurogene Inc. Approves Inducement Stock Option Grants for New Employees Under Nasdaq Rule 5635(c)(4) - geneonline.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Stock Market Recap: Is Neurogene Inc part of any major index2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Market Wrap: Does Neurogene Inc align with a passive investing strategy2026 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
Why is Neurogene (NGNE) Stock underperforming the market | Price at $22.07, Up 5.55%Turnaround Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Canaccord Genuity Remains a Buy on Neurogene (NGNE) - The Globe and Mail
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00 - Defense World
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group - MarketBeat
Will Neurogene (NGNE) Stock Miss Expectations | Price at $20.47, Down 1.06%Market Signals - Xã Thanh Hà
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Institution Moves: Is Neurogene Inc stock risky to hold nowQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Neurogene (NGNE) president and CFO Cvijic sells $55k in stock - Investing.com India
Neurogene (NGNE) president and CFO Cvijic sells $55k in stock By Investing.com - Investing.com South Africa
Neurogene (NGNE) CFO’s 2,558-share sale tied to mandatory RSU tax withholding - Stock Titan
Neurogene (NGNE) CEO McMinn logs small, tax-related sale after RSU vesting - Stock Titan
RSU tax sale: Neurogene (NGNE) CMO disposes 828 shares - Stock Titan
Pullback Watch: Will Neurogene Inc stock hit new highs in YEARTrade Risk Assessment & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Equities Analysts Set Expectations for Neurogene Q1 Earnings - MarketBeat
Neurogene (NGNE) Receives a Buy from LifeSci Capital - The Globe and Mail
Neurogene Inc (NGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):